Regulatory subunit type I-α of protein kinase A (PRKAR1A):: A tumor-suppressor gene for sporadic thyroid cancer

被引:74
作者
Sandrini, F
Matyakhina, L
Sarlis, NJ
Kirschner, LS
Farmakidis, C
Gimm, O
Stratakis, CA
机构
[1] NICHD, Unit Genet & Endocrinol, DEB, NIH, Bethesda, MD 20892 USA
[2] Russian Acad Sci, Inst Cytol & Genet, Siberian Dept, Novosibirsk 630090, Russia
[3] NIDDKD, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA
关键词
D O I
10.1002/gcc.10112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor-suppressor gene encoding the cyclic AMP-dependent protein kinase A type I-a regulatory subunit PRKAR1A has been mapped to chromosome 17 (17q22-24) and is mutated in Carney complex, a familial neoplasia syndrome that is associated with thyroid tumors. Other genes implicated in cyclic nucleotide-dependent signaling have been investigated in thyroid tumorigenesis. We studied protein kinase A (PKA) activity in noninherited follicular thyroid adenomas and follicular, papillary, and undifferentiated (anaplastic) thyroid carcinomas. We then examined these and additional thyroid tumors for losses of the 17q22-24 PRKAR1A region, mutations of the PRKAR1A gene, and expression of its peptide product. Total PKA activity was markedly increased in carcinomas over that in adenomas, whereas the ratio of free vs. total PKA activity was decreased in cancer. Consistent with these findings, the 17q22-24 region was frequently lost in cancer but not in benign adenomas. A novel inactivating mutation of the PRKAR1A gene (leading to premature termination of the predicted protein) was found in an aggressive thyroid cancer. The tumor with PRKAR1A gene mutation, as well as the tumors with 17q allelic losses, showed decreased PRKAR1A expression by immunostaining. We conclude that PRKAR1A, the most abundant regulatory subunit of protein kinase A and a principal cyclic AMP-signaling modulator, acts as a tumor-suppressor gene in sporadic thyroid cancer. Published 2002 Wiley-Liss, Inc.(dagger).
引用
收藏
页码:182 / 192
页数:11
相关论文
共 63 条
[1]   PAPILLARY THYROID-CARCINOMA ETIOLOGY, ASSESSMENT, AND THERAPY [J].
AIN, KB .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1995, 24 (04) :711-+
[2]  
[Anonymous], 1992, ATLAS TUMOR PATHOL
[3]  
ARMSTRONG R, 1995, MOL CELL BIOL, V15, P1826
[4]   MULTIPLE CUTANEOUS MYXOMAS COINCIDING WITH REPEATED CARDIAC MYXOMAS - A SYNDROME [J].
BIER, B ;
SEITZ, G ;
BACH, R ;
VOLKMER, I ;
FROHLIG, G .
THORACIC AND CARDIOVASCULAR SURGEON, 1989, 37 (05) :317-319
[5]  
BONAT S, 2000, P 82 ANN M END SOC T
[6]   MOLECULAR CHARACTERIZATION OF A THYROID TUMOR-SPECIFIC TRANSFORMING SEQUENCE FORMED BY THE FUSION OF RET TYROSINE KINASE AND THE REGULATORY SUBUNIT RI-ALPHA OF CYCLIC AMP-DEPENDENT PROTEIN KINASE-A [J].
BONGARZONE, I ;
MONZINI, N ;
BORRELLO, MG ;
CARCANO, C ;
FERRARESI, G ;
ARIGHI, E ;
MONDELLINI, P ;
DELLAPORTA, G ;
PIEROTTI, MA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :358-366
[7]  
Bosman FT, 1999, J PATHOL, V188, P1, DOI 10.1002/(SICI)1096-9896(199905)188:1<1::AID-PATH327>3.0.CO
[8]  
2-J
[9]   The 3',5'-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas [J].
Brunetti, A ;
Chiefari, E ;
Filetti, S ;
Russo, D .
ENDOCRINOLOGY, 2000, 141 (02) :722-730
[10]  
Carney JA., 1992, Endocrinologist, V2, P6, DOI [10.1097/00019616-199201000-00003, DOI 10.1097/00019616-199201000-00003]